Cotransplantation of mesenchymal stem cells with nonmyeloablative haploidentical peripheral blood stem cells without T cells deleted for high-risk acute leukemia: to reduce the severity of graft versus host disease and relapse

This study is testing a new strategy for people with high-risk acute leukaemia (blood cancer) who need a stem cell transplant from a partially matched family member (haploidentical transplant). This type of transplant can be complicated by the donor immune cells attacking the patient's body (graft-versus-host disease) or the body rejecting the new stem cells. Researchers are testing whether adding special cells called mesenchymal stem cells (MSCs) to the transplant can make it safer and more effective by supporting engraftment and reducing complications. You may be eligible if: - You have been diagnosed with high-risk acute leukaemia - You are between 9 and 60 years of age You may NOT be eligible if: - After chemotherapy, more than 50% of your bone marrow cells are still blast cells (immature cancer cells) Talk to your doctor about whether this trial might be right for you.